Mehmet Ozgur Cubuk1, Ahmet Yucel Ucgul2, Armagan Ozgur3, Kemal Ozulken4, Erdem Yuksel5,6. 1. Department of Ophthalmology, Istanbul Research and Education Hospital, Istanbul, Turkey. 2. Department of Ophthalmology, Bolu Abant Izzet Baysal University, Izzet Baysal Training and Research Hospital, Bolu, Turkey. 3. Department of Ophthalmology, Sanliurfa Training and Research Hospital, Sanliurfa, Turkey. 4. Faculty of Medicine, Department of Ophthalmology, TOBB University, Ankara, Turkey. 5. Faculty of Medicine, Department of Ophthalmology, Kastamonu University, Kastamonu, Turkey. rdmyksl@yahoo.com. 6. Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard University, 170 Gerry Road Chestnut Hill, Brookline, MA, 02467, USA. rdmyksl@yahoo.com.
Abstract
PURPOSE: To evaluate the clinical effect of topical cyclosporine A (CsA) (0.05%) on dry eye patients with Sjogren's syndrome (SS) and non-Sjogren's syndrome (NSS). METHOD: This retrospective comparative study includes the dry eye (DE) patients who were treated with topical CsA. DE patients were divided into two groups as follows: DE with Sjogren's syndrome (DE-SS) and DE with Non-Sjogren's syndrome (DE-NSS). Dry eye parameters were recorded at baseline and each visit. RESULTS: Schirmer's test 1 scores were 2.7 ± 0.5 mm at baseline and 3.5 ± 0.7 mm at 12th month in DE-SS, 2.9 ± 0.7 mm at baseline and 9.5 ± 0.7 mm in DE-NSS groups at 12th month. Mean ST score was higher in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (both p = 0.001). Tear break-up time score showed a significant improvement in DE-NSS group, and it was lower in DE-NSS group than DE-SS group group at sixth and 12th months of the treatment (p = 0.044 and 0.027, respectively). Mean OSDI score was lower in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (p = 0.030 and 0.032, respectively). CONCLUSION: Topical CsA seems to be more effective in the treatment of the DE-NSS.
PURPOSE: To evaluate the clinical effect of topical cyclosporine A (CsA) (0.05%) on dry eyepatients with Sjogren's syndrome (SS) and non-Sjogren's syndrome (NSS). METHOD: This retrospective comparative study includes the dry eye (DE) patients who were treated with topical CsA. DE patients were divided into two groups as follows: DE with Sjogren's syndrome (DE-SS) and DE with Non-Sjogren's syndrome (DE-NSS). Dry eye parameters were recorded at baseline and each visit. RESULTS: Schirmer's test 1 scores were 2.7 ± 0.5 mm at baseline and 3.5 ± 0.7 mm at 12th month in DE-SS, 2.9 ± 0.7 mm at baseline and 9.5 ± 0.7 mm in DE-NSS groups at 12th month. Mean ST score was higher in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (both p = 0.001). Tear break-up time score showed a significant improvement in DE-NSS group, and it was lower in DE-NSS group than DE-SS group group at sixth and 12th months of the treatment (p = 0.044 and 0.027, respectively). Mean OSDI score was lower in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (p = 0.030 and 0.032, respectively). CONCLUSION: Topical CsA seems to be more effective in the treatment of the DE-NSS.
Authors: F Brignole; P J Pisella; M Goldschild; M De Saint Jean; A Goguel; C Baudouin Journal: Invest Ophthalmol Vis Sci Date: 2000-05 Impact factor: 4.799
Authors: K Tsubota; K Fukagawa; T Fujihara; S Shimmura; I Saito; K Saito; T Takeuchi Journal: Invest Ophthalmol Vis Sci Date: 1999-01 Impact factor: 4.799
Authors: Fabiola Atzeni; Francesco Gozza; Giacomo Cafaro; Carlo Perricone; Elena Bartoloni Journal: Front Immunol Date: 2022-05-06 Impact factor: 8.786
Authors: Jiawei Ling; Ben Chung-Lap Chan; Miranda Sin-Man Tsang; Xun Gao; Ping Chung Leung; Christopher Wai-Kei Lam; Jiang-Miao Hu; Chun Kwok Wong Journal: Front Med (Lausanne) Date: 2022-01-17